Pharmacogenomic Analysis in Determining Optimal Drug Dosage in Chronic Disease Patients in Indonesia

Rosmerry Simanjuntak; Henny Sutrisman; Adrianus Prihartanto; Rossa Ramadhona

doi:10.62951/ijph.v1i3.74

Authors

Rosmerry Simanjuntak Philippine Women University institusi
Henny Sutrisman Philippine Women University institusi
Adrianus Prihartanto Philippine Women University institusi
Rossa Ramadhona Philippine Women University institusi

DOI:

https://doi.org/10.62951/ijph.v1i3.74

Keywords:

Pharmacogenomics, Optimal drug dosage, Chronic disease

Abstract

. Pharmacogenomics, the science that combines genetics with pharmacology, plays a vital role in determining the optimal dosage of drugs for patients, especially those with chronic diseases. In Indonesia, the use of pharmacogenomic approaches is still limited even though the genetically diverse population requires more personalized dosage adjustments. This study aims to analyze the effect of genetic variation on drug response in patients with chronic diseases, such as diabetes, hypertension, and cardiovascular disease, in Indonesia. By collecting and analyzing genetic data and patient clinical data, this study will identify genetic biomarkers associated with drug metabolism and therapeutic effectiveness. The results of this study are expected to provide guidance for more accurate and personalized drug dosage determination, which will ultimately improve therapeutic outcomes and reduce the risk of side effects. This study is also expected to encourage wider adoption of pharmacogenomic approaches in clinical practice in Indonesia, as part of the effort towards more personalized and effective medicine.

Downloads

Download data is not yet available.

References

Indonesian Ministry of Health. (2018). Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia.

Yasuda, S., Zhang, L., Huang, S. M. (2008). The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies. Clinical Pharmacology & Therapeutics, 84(3), 417-423.

Lee, Y. M., Ryu, J. M., Kim, J. H., & Park, H. K. (2015). Genetic variants in CYP2C19 and their clinical relevance in drug response among Asians. Pharmacogenomics, 16(4), 393-405.

Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & Therapeutics, 116(3), 496-526.

Kurniati, R., Purwanto, D. J., & Setiawan, D. A. (2019). Genetic variation of CYP2C9 and CYP2C19 among Indonesian ethnicities and its clinical implication on drug metabolism. Journal of Clinical Pharmacology, 59(5), 697-705.

Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T., Limdi, N. A., Page, D., Roden, D. M., Wagner, M. J., & Caldwell, M. D. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England Journal of Medicine, 360(8), 753-764.

Yamamoto, K., Komuro, S., & Sakuraba, H. (2001). Variability of pharmacokinetics and pharmacodynamics among Asian populations: the implications of pharmacogenetics. British Journal of Clinical Pharmacology, 52(4), 429-432.

Johnson, J. A., & Cavallari, L. H. (2015). Warfarin pharmacogenetics: update and future directions. Pharmacotherapy, 35(12), 1162-1174.

Zhou, S. F., Di, Y. M., Chan, E., Du, Y. M., Chow, V. D., Xue, C. C., Lai, X., Duan, W., & Li, C. G. (2008). Clinical pharmacogenetics and potential application in personalized medicine. Current Drug Metabolism, 9(8), 738-784.